Ir para o conteúdo principal

Nurix Therapeutics Inc (NASDAQ: NRIX) — Perfil da empresa, notícias e dados financeiros

Logo de Nurix Therapeutics Inc
NRIX Nurix Therapeutics Inc
Nurix Therapeutics Inc primary media
Perfil da empresa

Nurix Therapeutics Inc

Nurix Therapeutics (NASDAQ:NRIX) focuses on discovering, developing, and commercializing small molecule therapies designed to control the body’s protein levels. Leveraging proprietary platforms to manipulate the ubiquitin-proteasome system, their goal is to advance a pipeline of novel therapies targeting critical areas including oncology, inflammation, and immune disorders. Nurix is committed to pushing the boundaries of medical science to create treatments that improve patient outcomes and address unmet medical needs. Through strategic collaborations and internal research, they aim to harness the power of protein degradation to bring innovative medicines from the lab bench to patients in need.

Resumo

Public USParticipação acionária
2009Ano de fundação
284Funcionários
San Francisco, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
San Francisco, US

Produtos e/ou serviços de Nurix Therapeutics Inc

  • DeTIL-0255, a cell therapy using engineered T cells and tumor-infiltrating lymphocytes for advanced solid tumors.
  • NX-2127, an orally bioavailable degrader targeting BTK and IMiDs for B-cell malignancies.
  • NX-1607, a CBL-B inhibitor designed to stimulate the immune system against solid tumors.
  • NX-5948, a brain-penetrant BTK degrader for B-cell malignancies and autoimmune diseases.
  • Research collaboration with Sanofi focusing on developing novel targeted protein degradation therapies.
  • Partnership with Gilead Sciences to discover, develop, and commercialize a pipeline of innovative targeted protein degradation drugs.

equipe executiva do Nurix Therapeutics Inc

  • Arthur T. SandsCEO, President & Director
  • Johannes Van HouteChief Financial Officer
  • Gwenn M. HansenChief Scientific Officer
  • Christine RingChief Legal Officer, Secretary & Chief Compliance Officer
  • John KuriyanFounder & Member of Scientific Advisory Board
  • Arthur WeissFounder & Member of Scientific Advisory Board
  • Rita KwongSenior Accounting Manager
  • Pasit PhiasivongsaChief Technical Officer
  • Wesley BurwellChief Human Resources Officer
  • Jason KantorChief Business Officer

Principais indicadores financeiros

Resultados divulgados pela Nurix Therapeutics Inc, em USD.

Cap. de mercado
3 bi
Receita (TTM)
701,9 mi
P/L
11.2
LPA (diluído, TTM)
2.4
Dividend yield
—
Margem de lucro
42.0%
Receita e lucro anuais da Nurix Therapeutics Inc
Fim do ano fiscalReceitaResultado operacionalLucro líquido
84 mi-285,7 mi-264,5 mi
54,5 mi-213 mi-193,6 mi
77 mi-155,1 mi-143,9 mi
38,6 mi-183,9 mi-166 mi